Iodinated contrast media (ICMs) are widely administered for diagnostic and interventional procedures. Despite their generally excellent safety record, adverse drug reactions (ADRs) still occur, ranging from minor disturbances to fatal complications, in very rare cases.^[@b1],[@b2]^

Because of relatively small numbers of patients included in controlled clinical trials for initial drug approval, it is usually difficult to determine the true occurrence and frequency of ADRs associated with a drug. Post-marketing surveillance (PMS) studies, therefore, provide an opportunity to obtain further knowledge of safety and tolerability of an approved drug, including ICMs, in a "real-world" setting. The framework of a PMS programme enables prospective data to be collected from a very large non-selected patient population.^[@b3]^

The primary purpose of this study was to determine the ADR profile of iodixanol as used in routine clinical practice. Additionally, patient comfort profile following iodixanol administration was assessed.

METHODS AND MATERIALS {#s1}
=====================

Study design
------------

This was a prospective, non-interventional, non-randomized, multicentre, open-label, observational study carried out across 95 centres in China from June 2011 to October 2012. The study was registered at ChiCTR-ONC (11003061) and was sponsored by GE Healthcare, Shanghai, China.

Investigational review board approval was obtained where it was required. The study was conducted in full accordance with the principles of the Declaration of Helsinki and the good clinical practice (GCP) guidelines and adhered to the regulatory requirements and laws of China. The study population was clearly defined in the clinical study protocol along with other rigorous unambiguous inclusion/exclusion criteria. The principal investigator at each site was responsible for recruiting eligible patients to the trial and was to abide by the protocol throughout the course of the study. Data management and statistical analyses were conducted by an independent clinical research organization (Hangzhou Tigermed Consulting Co., Ltd, Hangzhou, China).

Observational plan
------------------

The safety surveillance started immediately following iodixanol administration and continued for 7 days after ICM administration. A standardized questionnaire, which permitted the systematic and integrated analysis of the data, was used to collect occurrence of ADRs. Inclusion and exclusion criteria of the protocol were consistent with the indications and contraindications specified in the local package insert. Written informed consent was obtained for every subject, either from the subject themselves or from a legally acceptable representative, before any procedure or assessment was done---after the aims, methods, anticipated benefits and potential hazards were explained. Iodixanol was administered in a routine manner according to the diagnostic indication and need or consistent with each institution\'s practising protocol. Pre-treatment (such as H~1~ antagonist or H~2~ antagonist and steroid) and the type of pre-treatment were based on the institutional standard. No specific criterion was established in the study.

Observational variables
-----------------------

The following data were collected from each patient and recorded in case report forms: patient demographics in conformance with local regulations, medical history and relevant underlying diseases (*e.g.* allergies, diabetes mellitus (DM), renal insufficiency, coronary heart disease, proteinuria, gout and arterial hypertension), pre-medication, type of examination/intervention, volume and dose of iodixanol administered, route of administration (intra-arterial (i.a.) or intravenous (i.v.)), status of vein/artery punctured, mode of injection (manually or using power injector), pre-heating iodixanol to body temperature before administration or not and overall tolerance to ICM.

Any immediate ADR (occurred within 1 h after ICM administration)^[@b4]^ or delayed ADR (occurred \>1 h to 7 days after ICM administration)^[@b5]^ was recorded in the separate questionnaire regarding the type of signs/symptoms, onset time, lasing duration, severity, causal relationship and outcome. In addition, each ADR was evaluated for seriousness and was designated as a serious ADR if it met one of the following criteria: fatal or life-threatening, leading to significant or permanent damage/impairment or requiring hospitalization in an intensive care unit, hospital stay prolongation or leading to congenital anomalies. For those patients who experienced an ADR after iodixanol administration, the additional data were documented, including history of allergies, other relevant anamnestic features, previous ICM examinations, previous reactions to ICM, concomitant diseases (except the indication) and concomitant medications. No laboratory tests were required or collected.

Injection-associated patient discomfort was enquired about immediately after administration of iodixanol. Patients were asked to report and rate discomfort, such as pain at the injection site and sensations of coldness or heat in the injected vessel. Scores were reported verbally by the patient on a scale from 0 (no discomfort) to 10 (severe discomfort).

Statistical plan and analysis
-----------------------------

The study sample size of approximately 20 000 was estimated based on previously published statistical calculations for PMS studies, which allows rare ADRs to be studied with an incidence of approximately 1.5/10 000.^[@b4],[@b6]^

Data analysis was performed using SAS^®^ software v. 9.2 (SAS Institute Inc., Chicago, IL). Patient data obtained from all sites were pooled into an integrated database. Data were analysed using descriptive statistical methods (*e.g.* frequency tables and descriptive statistical parameters). Pearson\'s *χ*^2^ test was used to analyse differences between different groups. Multivariants logistic regression analysis was performed to assess independent contributing factors to ADRs.

RESULTS {#s2}
=======

Patient demographics and baseline characteristics
-------------------------------------------------

A total of 20 185 unselected patients were included in the study during a 16-month period. Patient demographic data and baseline characteristics are shown in [Table 1](#tbl1){ref-type="table"}. The mean age of patients was 60.4 ± 12.8 years, with 42.8% of them between 51 and 65 years. 65% of the patients included in the study had one or more risk factors or the presence of underlying disease. Using criteria described by the Contrast Media Safety Committee of the European Society of Urogenital Radiology 7.0,^[@b7]^ 65.4% of patients (13 203/20 185) reported 1 or more risk factors for contrast administration. The details on the risk factors are presented in [Table 2](#tbl2){ref-type="table"}. Pre-medication was administered to 2794 patients (13.8%), with the most common one being steroid (12.4%); H~1~ antagonist accounted for only 0.6%.

###### 

Patient demographic and baseline characteristics (all enrolled patients)

  Characteristics            *n* (%)
  -------------------------- ---------------
  Total patient population   20 185
   Male                      12 734 (63.1)
   Female                    7451 (36.9)
  Mean age (years)           60.4
  Age range (years)          5--100
  Age range (years)           
   \<18                      9 (0.0)
   18--35                    638 (3.2)
   36--50                    3746 (18.6)
   51--65                    8646 (42.8)
   \>65                      7146 (35.4)
  Mean body weight (kg)      66.59

###### 

Patients with baseline risk factors (all enrolled patients)

  Characteristics                             *n* (%)
  ------------------------------------------- ---------------
  Patients with risk factors                   
   Yes                                        13 203 (65.4)
   No                                         6982 (34.6)
  Impaired renal function                     435 (2.2)
  Prior kidney surgery                        68 (0.3)
  Gout                                        130 (0.6)
  Hypertension                                8333 (41.3)
  Heart insufficiency                         825 (4.1)
  Coronary heart disease                      5555 (27.5)
  Diabetes requiring treatment                2796 (13.9)
  Asthma                                      67 (0.3)
  Previous moderate--severe reaction to ICM   16 (0.1)
  \>70 years old                              4944 (24.5)

ICM, iodinated contrast medium.

Type of examination and usage of iodixanol
------------------------------------------

The most common type of imaging examinations was contrast-enhanced CT (CECT) (25.6%), followed by coronary angiography (CAG) (20.4%), percutaneous coronary intervention (PCI) (19.5%), coronary CT angiography (CCTA) (17.8%) and interventional radiology (16.8%) ([Table 3](#tbl3){ref-type="table"}).

###### 

Examination type and iodixanol administration information (all enrolled patients)

  Parameter                                    Statistics        *n* (%)
  -------------------------------------------- ----------------- ---------------
  Examination type                             CECT              5158 (25.6)
  CCTA                                         3585 (17.8)       
  Diagnostic CAG                               4114 (20.4)       
  CAG + PCI                                    3940 (19.5)       
  IR                                           3391 (16.8)       
  Iodixanol concentration                      270 mg I ml^−1^   379 (1.9)
  320 mg I ml^−1^                              19 806 (98.1)     
  Contrast pre-heated to body temperature      Yes               8760 (43.4)
  No                                           11 425 (56.6)     
  Status of artery/vein                        Good              18 093 (89.6)
  Moderate                                     1898 (9.4)        
  Poor                                         174 (0.9)         
  Contrast volume (ml)                         Mean              95.9
  Min--max                                     20--600           
  Contrast volume category (ml)                0--50             2838 (14.1)
  51--80                                       6727 (33.3)       
  81--100                                      7321 (36.3)       
  \>100                                        3299 (16.3)       
  Administration route                         Artery            11 049 (54.7)
  Vein                                         9112 (45.1)       
  Other^[*a*](#tblfn1){ref-type="table-fn"}^   24 (0.1)          
  Injection mode                               Manual            7238 (35.9)
  Automatic                                    12 653 (62.7)     
  Manual and automatic                         293 (1.5)         
  Other^[*b*](#tblfn2){ref-type="table-fn"}^   1 (0.0)           
  Flow rate (ml s^−1^)                         Mean              4.28
  Min--max                                     1.0--25.0         
  Flow rate category (ml s^−1^)                ≤2                408 (2.0)
  2--3                                         4071 (20.2)       
  3--4                                         2908 (14.4)       
  4--5                                         3531 (17.5)       
  \>5                                          1766 (8.7)        

CAG, coronary angiography; CCTA, coronary CT angiography; CECT, contrast-enhanced CT; IR, interventional radiology; max, maximum; min, minimum; PCI, percutaneous coronary intervention.

Administration route: other included oral, oesophageal, biliary tract, subcutaneous, or percutaneous bilateral renal calyces administration.

Injection mode: other is oesophageal dosing.

Iodixanol 320 mg I ml^−1^ was the most frequently used concentration (in 98.1% of examinations). The route of administration was i.v. in 9112 (45.1%) cases, i.a. in 11 049 (54.7%) of the cases and by other means in 24 (0.1%) of the cases. The contrast was most frequently delivered by a power injector (62.7% of procedures), followed by manual injection (35.9%) and manual plus power injection (1.5%). The mean (±standard deviation) volume of iodixanol was 95.9 (±46.2) ml with a median flow rate of 4.28 ml s^−1^. In 43.4% patients, iodixanol was warmed to 37 °C prior to use. The status of punctured arteries/veins during the examination was"good" in 18 093 (89.6%) patients, "moderate" in 1898 (9.4%) patients and "poor" in 174 (0.9%) patients ([Table 3](#tbl3){ref-type="table"}).

Adverse drug reactions
----------------------

### Overall summary of adverse drug reactions

The overall incidence of ADRs in the study was 1.52% (307/20 185). Of which, immediate ADRs were 0.58% (117/20 185) and delayed ADRs were 0.97% (195/20 185). Five patients developed both types of reactions, and two patients had serious ADRs (0.01%) ([Table 4](#tbl4){ref-type="table"}). The two patients with serious ADRs had acute anaphylactic shock that resolved after treatment. There were no permanent injuries or deaths reported in any of the patients. The most common immediate ADRs were gastrointestinal disorders (*n* = 45, 0.22%), followed by skin and subcutaneous tissue disorders (*n* = 39, 0.19%) and nervous system disorders (*n* = 12, 0.06%). For the delayed ADRs, skin subcutaneous tissue disorders, including rash, pruritus, skin and mucosa erythema, occurred in 138/20 185 patients (0.68%), with rash being the highest (0.39%, 78/20 185 cases), followed by general disorders and administration site conditions, including pyrexia and face oedema in 21/20 185 cases (0.10%), then immune system disorders, including hypersensitivity, in 18/20 185 patients (0.09%).

###### 

Summary of adverse drug reactions (ADRs) by system organ class/preferred terms and onset time (incidence ≥0.05%) (all enrolled patients)

  Parameter                                              Immediate onset of ADRs, *n* (%)   Delayed onset of ADRs, *n* (%)   Both onsets of ADRs, *n*   Total no. of events
  ------------------------------------------------------ ---------------------------------- -------------------------------- -------------------------- ---------------------
  Patients with at least one ADR                         117 (0.58)                         195 (0.97)                       5                          371
  Skin and subcutaneous tissue disorders                 39 (0.19)                          138 (0.68)                       3                          195
   Rash                                                  15 (0.07)                          78 (0.39)                        2                          93
   Hives                                                 12 (0.06)                          18 (0.09)                        1                          30
   Pruritus                                              5 (0.02)                           11 (0.05)                        0                          16
   Mucocutaneous rash                                    1 (0.00)                           11 (0.05)                        0                          12
   Swelling face                                         0                                  10 (0.05)                        0                          10
  Immune system disorders                                5 (0.02)                           18 (0.09)                        1                          23
   Hypersensitivity                                      3 (0.01)                           17 (0.08)                        0                          20
  Gastrointestinal disorders                             45 (0.22)                          9 (0.04)                         3                          56
   Nausea                                                27 (0.13)                          4 (0.02)                         2                          31
   Vomiting                                              16 (0.08)                          2 (0.01)                         1                          18
  General disorders and administration site conditions   11 (0.05)                          21 (0.10)                        1                          36
  Nervous system disorders                               12 (0.06)                          11 (0.05)                        2                          27
   Dizziness                                             7 (0.03)                           7 (0.03)                         0                          14
  Respiratory, thoracic and mediastinal disorders        5 (0.02)                           4 (0.02)                         0                          11

### Incidences of adverse drug reactions in subgroups

There were notable differences in ADR rates in the different types of examinations: it was significantly higher for CCTA/CECT than for other procedures (*p* \< 0.001) ([Table 5](#tbl5){ref-type="table"}). Among patients aged older than 18 but less than 70 years, the incidence of ADRs was higher than in those aged over 70 years (1.76% *vs* 0.69%, *p* \< 0.001) ([Table 6](#tbl6){ref-type="table"}; [Figure 1](#fig1){ref-type="fig"}). Further age group analysis showed that significantly more ADRs were reported in the 18- to 40-year group (2.42%) *vs* the 41- to 70-year group (1.7%) and aged over 70 years group (0.76%) (*p* = 0.0001). The incidence of ADRs in patients who received pre-heated iodixanol was higher than in those who received non-heated iodixanol (1.84% *vs* 1.28%, *p* = 0.001). For patients with a "good" status of punctured vessels, the ADR rates were significantly higher in patients with punctured veins than in those with punctured arteries (*p* \< 0.001). The ADR rates were higher in patients with "poor" status of punctured veins than in those with "moderately" punctured veins (5.81% *vs* 1.70%, *p* = 0.023). Significant differences in ADR rates were found with different contrast delivery methods: use of a power injector was associated with 1.98% of ADRs; manual and power injection, 1.02%; and manual injector, 0.73% (*p* \< 0.001). The incidence of ADRs in patients who received \<50 ml iodixanol was 1.34%; 50--100 ml was 1.62%; and \>100 ml was 1.24%. The differences among the three dose groups were not statistically significant (*p* \> 0.05) ([Table 6](#tbl6){ref-type="table"}).

###### 

Incidence of adverse drug reactions (ADRs) by examination type

  Examination type              Parameter   Patients with ADRs, *n* (%)    95% CI (%)
  ---------------------------- ----------- ----------------------------- --------------
  CECT, *N* = 5158                 ADR              111 (2.15)            1.756, 2.548
  Serious ADR                       0                                    
  Immediate onset               42 (0.81)          0.569, 1.060          
  Delayed onset                 70 (1.36)          1.041, 1.673          
  CCTA, *N* = 3585                 ADR              114 (3.18)            2.606, 3.754
  Serious ADR                       0                                    
  Immediate onset               45 (1.26)          0.891, 1.620          
  Delayed onset                 72 (2.01)          1.549, 2.468          
  Diagnostic CAG, *N* = 4114       ADR               27 (0.66)            0.410, 0.903
  Serious ADR                       0                                    
  Immediate onset               11 (0.27)          0.110, 0.425          
  Delayed onset                 17 (0.41)          0.217, 0.609          
  CAG + PCI, *N* = 3940            ADR               35 (0.89)            0.595, 1.181
  Serious ADR                   2 (0.05)           0.000, 0.121          
  Immediate onset               14 (0.36)          0.170, 0.541          
  Delayed onset                 21 (0.53)          0.306, 0.760          
  IR, *N* = 3391                   ADR               21 (0.62)            0.355, 0.883
  Serious ADR                       0                                    
  Immediate onset               6 (0.18)           0.035, 0.318          
  Delayed onset                 15 (0.44)          0.219, 0.666          

CAG, coronary angiography; CCTA, coronary CT angiography; CECT, contrast-enhanced CT; CI, confidence interval; IR, interventional radiology; PCI, percutaneous coronary intervention.

Immediate onset---occurring within 1 h of the administration of iodixanol.

Delayed onset---occurring after 1 h up to 7 days after administration of iodixanol.

###### 

Comparison of incidences of adverse drug reactions (ADRs) in different groups (all enrolled patients)

  Variables                        Incidences of ADRs, *n* (%)   *p*-value
  ------------------------------- ----------------------------- -----------
  Age (years)                                                         
   ≤70                                     247 (1.89)                 
   \>70                                     60 (0.84)             \<0.001
  Dose (ml)                                                           
   \<50 *vs* 50--100                38 (1.34) *vs* 228 (1.62)      0.284
   \<50 *vs* \>100                  38 (1.34) *vs* 41 (1.24)       0.735
   50--100 *vs* \>100               228 (1.62) *vs* 41 (1.24)      0.118
  Status of arterial puncturing                                       
   Good *vs* moderate                81 (0.79) *vs* 2 (0.28)       0.177
   Good *vs* poor                    81 (0.79) *vs* 0 (0.00)       1.000
   Moderate *vs* poor                2 (0.28) *vs* 0 (0.00)        1.000
  Status of venous puncturing                                         
   Good *vs* moderate               199 (2.54) *vs* 20 (1.70)      0.084
   Good *vs* poor                   199 (2.54) *vs* 5 (5.81)       0.070
   Moderate *vs* poor                20 (1.70) *vs* 5 (5.81)       0.023
  Pre-heating                                                         
   Yes                                     161 (1.84)                 
   No                                      146 (1.28)              0.001

![Incidence of adverse drug reactions by risk factors.](bjr.20130325.g001){#fig1}

### Adverse drug reactions and risk factor correlations

Comparison of the ADR rates between patients with and without risk factors revealed that patients with a history of previous ICM reaction were associated with increased rates of ADR (*p* = 0.024). Patients with hypertension had a significantly lower rate of ADRs than those without hypertension (1.30% *vs* 1.68%, *p* = 0.031). There was no difference between the ADR rates of patients pre-treated with H~1~ and H~2~ antihistamines or corticosteroids and those without pre-treatment (1.72% with pre-treatment *vs* 1.49% without, *p* = 0.3595).

In the multivariate analysis for the ADRs to identify independent contributing factors, the following variables were included in the model: previous reaction to ICM (yes *vs* no), age category (\<65 *vs* ≥65 years old), weight category (\<80 *vs* ≥80 kg), gender (male *vs* female), contrast flow rate (\<4 *vs* ≥4 ml s^−1^), administration route (artery *vs* vein or other route), total contrast volume (\<100 *vs* ≥100 ml), contrast concentration (320 *vs* 270 mg I ml^−1^), pre-heating (yes *vs* no), kidney disease (yes *vs* no), cardiac disease (yes *vs* no), gout (yes *vs* no), DM (yes *vs* no) and asthma (yes *vs* no). The result of this analysis is presented in [Table 7](#tbl7){ref-type="table"}. Female gender, i.v. route of administration, age less than 65 years, body weight ≥80 kg, contrast flow rate ≥4 ml s^−1^ and prior reaction to ICM were identified as significant contributors to ADRs. None of the other variables was a significant factor.

###### 

Multivariable logistic regression analyses determining the effect of different factors on adverse drug reactions

  Variable                                                                 Estimate (SE)          OR             95% CI         *p*-value
  -------------------------------------------------------------------- ---------------------- ----------- -------------------- -----------
  Iodixanol (mg I ml^−1^), 320 *vs* 270                                  13.4255 (307.2000)    \>999.990   \<0.001, \>999.990    0.9651
  Artery *vs* vein + others^[a](#tblfn3){ref-type="table-fn"}^ route      −1.6393 (0.2447)       0.194        0.120, 0.314      \<0.0001
  Pre-heating, yes *vs* no                                                0.2727 (0.1364)        1.314        1.005, 1.716       0.0455
  Contrast volume (ml), ≥100 *vs* \<100                                   0.0733 (0.1642)        1.076        0.780, 1.485       0.6551
  Flow rate (ml s^−1^), ≥4 *vs* \<4                                       0.6126 (0.1451)        1.845        1.389, 2.452      \<0.0001
  Age (years), ≥65 *vs* \<65                                              −0.7694 (0.1691)       0.463        0.333, 0.645      \<0.0001
  Gender, male *vs* female                                                −0.4780 (0.1391)       0.620        0.472, 0.814       0.0006
  Weight (kg), ≥80 *vs* \<80                                              0.5172 (0.1764)        1.677        1.187, 2.370       0.0034
  Kidney disease, yes *vs* no                                           −12.2128 (2234.5000)    \<0.001    \<0.001, \>999.990    0.9956
  Cardiac disease, yes *vs* no                                            −0.4587 (0.7218)       0.632        0.154, 2.601       0.5251
  Gout, yes *vs* no                                                       0.1156 (1.0213)        1.123        0.152, 8.309       0.9098
  Hypertension, yes *vs* no                                               −0.0507 (0.1497)       0.951        0.709, 1.275       0.7350
  Diabetes mellitus, yes *vs* no                                          −0.0379 (0.2353)       0.963        0.607, 1.527       0.8721
  Asthma, yes *vs* no                                                     0.3316 (1.0212)        1.393       0.188, 10.310       0.7454
  Prior reaction to ICM, yes *vs* no                                      2.3264 (0.8078)       10.241       2.102, 49.886       0.0040

CI, confidence interval; ICM, iodinated contrast media; OR, odds ratio; SE, standard error.

Administration route: other included oral, oesophageal, biliary tract, subcutaneous, or percutaneous bilateral renal calyces administration.

Patient discomfort after iodixanol contrast administration
----------------------------------------------------------

### Pain

A total of 94.3% (19 044/20 185) patients in this study had no pain after the injection of iodixanol, whereas 5.7% of the patients experienced various degrees of pain: 5.3% of these (1065/20 185 patients) had mild pain (score, 1--3), 0.4% (74/20 185) had moderate pain (score, 4--7) and only 2 patients had severe pain (score, 8--10) ([Table 8](#tbl8){ref-type="table"}).

###### 

Summary of patient discomfort

  Discomfort, category/score    Pain, *n* (%)   Heat, *n* (%)   Cold, *n* (%)   Composite score   Number of patients
  ---------------------------- --------------- --------------- --------------- ----------------- --------------------
  None/0                        19 044 (94.3)   15 288 (75.7)   19 806 (98.1)          0            14 791 (73.3)
  Mild/1--3                      1065 (5.3)      4134 (20.5)      347 (1.7)          1--3            4338 (21.5)
  Moderate/4--7                   74 (0.4)        736 (3.6)       29 (0.1)           4--15            1054 (5.2)
  Severe/8--10                     2 (0.0)        27 (0.1)         3 (0.0)           \>15              2 (0.0)

### Heat

In this study, 75.7% of patients (15 288/20 185) experienced no heat sensation after injection of iodixanol, whereas 24.3% of them had various degrees of heat sensation: 20.5% (4134 patients) had mild (score, 1--3), 3.6% (736 patients) had moderate (score, 4--7) and 0.1% (27 patients) had severe (score 8--10) heat sensation ([Table 8](#tbl8){ref-type="table"}).

### Coldness

Most patients (19 806/20 185, 98.1%) did not report feeling cold at all. Only 1.9% of them had various degrees of feeling cold: 1.7% (347 patients) had mild (score, 1--3), 0.1% (29 patients) had moderate (score, 4--7) and 3 patients had severe (score, 8--10) cold sensation ([Table 8](#tbl8){ref-type="table"}).

### Composite score

The individual categorical scores (0--10) for pain, coldness and heat were combined to form a composite score (up to 30). Score 0, *i.e.* no discomfort, was seen in 14 791/20 185 patients (73.3%), score 1--3 in 4338/20 185 patients (21.5%), score 4--15 in 1054/20 185 patients (5.2%) and a composite score \>15 was seen in 2 patients in this study ([Table 8](#tbl8){ref-type="table"}). In patients with a "poor" status of punctured vessels, 71.8% (125/174 patients) reported some discomfort (composite score ≥1) compared with 45.9% (871/1898 patients) with a "moderate" and 24.3% (4393/28 093 patients) with a "good" status of punctured vessels. Patients who received pre-heated iodixanol were also more likely to report a composite score of 1--30 than those who received non-heated iodixanol (2972/8760 patients or 33.9% *vs* 2422/11 425 patients or 21.2%, respectively). In the assessment of composite score in the different types of examinations, a composite score of 1--30 was seen in 50.0% of CCTA examinations, followed by CECT (30.2%). A composite score of 1--10 was more frequently seen in the use of a power injector (4222/12 653 patients, 33.37%) than in the use of manual injection (1031/7238 patients, 14.24%).

DISCUSSION {#s3}
==========

We investigated the incidence of ADRs following the use of iso-osmolar non-ionic dimeric X-ray contrast agent, iodixanol, in 20 185 non-selected patients who underwent routine clinical imaging examinations at 95 centres in China. With this large database for iodixanol, we are able to understand its risk--benefit profile relative to other ICMs in use today.

The incidence of ADRs following non-ionic ICM administration has been reported ranging from 0.6% to 2.3% in most published studies,^[@b8],[@b9]^ with one notable exception of 5.0% by Munechika et al^[@b5]^ after using iohexol for urography and CT. In our study, the overall ADR rate of 1.52% (immediate ADRs, 0.58%, and delayed ADRs, 0.97%, respectively) is in line with those reported for other non-ionic ICMs using a comparable methodology ([Table 9](#tbl9){ref-type="table"}).^[@b4]--[@b13]^ The occurrence of serious ADRs was extremely rare (0.01%) and comparable to the findings of a meta-analysis (0.031%),^[@b14]^ which compared non-ionic ICMs with ionic high-osmolar ICMs. There were statistically significant differences in the rates of ADRs for the route of administration and status of punctured veins. Despite lower average doses of iodixanol being administered through the i.v. route compared with the i.a. route, higher ADRs were reported in the i.v. administration group and in patients with a "poor" status of punctured veins, which supports some previous findings.^[@b4],[@b15]^ In addition, the method of administration also appears to be related to occurrences of ADRs: more patients reported ADRs when iodixanol was administered via a power injector than via manual injections. This finding is also supported by other literature.^[@b4],[@b16]^ We observed that patients undergoing CCTA or CECT had a significantly higher rate of ADRs than those undergoing CAG and/or PCI (*p* \< 0.001, respectively). This finding may have arisen, in part, because patients undergoing CCTA or CECT received i.v. contrast medium injections. Patients in the age group 18--70 years experienced a higher rate of ADRs than those in the over 70 years age group. Further analysis revealed that more ADRs occurred in the 18--41 years age group, which is similar to previous reports.^[@b4],[@b8]^ The higher rate of ADRs in the younger patient group might be attributable to a higher immunocompetence among younger adults, suggesting that an immune-mediated process is involved.^[@b8]^ This theory is also supported by the lack of any significant association of the ADRs with the concentration and dose of iodixanol.

###### 

Summary of adverse drug reactions (ADRs) following iodinated contrast media administrations in other clinical trials

  Reference                                Procedure             Contrast medium     *n*                   ADR rates (%)                
  ----------------------------- ------------------------------- ----------------- --------- ------------------------------------------- ----------------------
  Kopp et al^[@b4]^                   X-ray examinations            Iopromide      74 717    1.50^[*a*](#tblfn4){ref-type="table-fn"}^           0.02
  Munechika et al^[@b5]^         Intravenous urography or CECT       Iohexol        7505     5.00^[*b*](#tblfn5){ref-type="table-fn"}^            /
  Häussler^[@b6]^                            CECT                   Iodixanol       9515                       0.74                              0.05
  Petersein et al^[@b8]^             Diagnostic procedures         Iobitridol      61 754    2.30^[*c*](#tblfn6){ref-type="table-fn"}^          1 died
  Mortelé et al^[@b10]^                      CECT                   Iopromide      29 508                      0.70                               /
  Vogl et al^[@b11]^                  X-ray examinations           Iobitridol      52 057                      0.96                             0.044
  Wendt-Nordahl et al^[@b12]^        Intravenous urography         Iobitridol      49 975    0.90^[*d*](#tblfn7){ref-type="table-fn"}^   1 anaphylactic shock
  Maurer et al^[@b9]^                 X-ray examinations           Iobitridol      160 000                     0.60                               /
  Palkowitsch et al^[@b13]^           X-ray examinations            Iopromide      44 835                      2.80                              0.02

CECT, contrast-enhanced CT.

Acute reactions.

Delayed adverse reactions.

1.1% had "feeling of warmth".

Acute adverse events (non-serious and transient).

Importantly, this large study enables us to identify contributing factors to ADRs. We found that ADRs were significantly more common in patients with a history of allergic reaction to ICMs (12.5% *vs* 1.51%; *p* = 0.024), which confirms that patients with allergies and/or prior hypersensitivity reactions to ICMs are indeed at an increased risk for developing ADRs. This is in agreement with Häussler,^[@b6]^ who found that patients with allergic diathesis appeared to be at an increased risk of immediate and delayed ADRs, and with Kopp et al,^[@b4]^ who reported significantly more immediate ADRs in this type of patient (7.4% *vs* 1.2%; *p* \< 0.001). Patients with hypertension were found to have a lower rate of ADRs than those without, in the group comparison. However, this significant difference disappeared in the multivariant logistical regression analyses (*p* = 0.7386), presumably because it was just a confounding but not true contributing factor to ADRs.

It has been debatable whether pre-treatment can reduce ADRs among high-risk patients. Vogl et al^[@b11]^ did not find an effect of pre-treatment on the occurrence of adverse reactions in patients with a history of asthma and/or allergies, whereas Kopp et al^[@b4]^ reported a slight decrease in the overall adverse event rate, but the difference was not significant (1.6% without *vs* 1.4% with pre-treatment). This may be attributable to the fact that the underlying pathophysiology of allergic reactions is not yet fully understood; therefore, many allergic ICM reactions are unpredictable,^[@b17]^ and, therefore, unpreventable. It is fortunate that the ADR rate is very low following non-ionic ICM administration, even in high-risk patients, which is certainly confirmed by our study results.

The effect of pre-heating ICMs on ADR risk has been somewhat controversial. Vergara and Seguel^[@b18]^ reported a reduction in adverse events after the warming of i.v. ICM, whereas in another retrospective study,^[@b19]^ adverse event rates were not affected by warming iopamidol to body temperature prior to i.v. administration for CT. In our study, warming iodixanol to 37 °C prior to administration resulted in an increase in the number of ADRs. It is not clear to us what might be responsible for this phenomenon.

As with findings from previous studies,^[@b4]^ female patients in this study reported a significantly higher rate of ADRs than male patients \[odds ratio (OR) = 0.621, 95% confidence interval (CI): 0.473, 0.815\]. We also found that body weight (\>80 kg) was an independent predictor of ADRs (OR = 1.657, 95% CI: 1.173, 2.341) along with a contrast flow rate ≥4 ml s^−1^ (OR = 1.846, 95% CI: 1.389, 2.452). These results are both clinically plausible and logical.

Discomfort characterized by pain, warmth and cold in connection with injection are common adverse effects associated with the use of intravascular ICMs. In some controlled clinical trials, more than one-third of patients reported injection-related discomfort, particularly local pain and an intense unpleasant sensation of warmth following ICM administration.^[@b20]^ The degree of discomfort and tolerability, generally considered to be directly proportional to the osmolality of the ICM, can influence the quality of the examination. Pain and discomfort may cause patients to move, thus resulting in motion artefacts and suboptimal images.^[@b21]^ Reduction in pain and discomfort is an important goal for improving the overall tolerability of any procedure. In line with earlier PMS study findings,^[@b6]^ a high proportion of patients tolerated iodixanol injection well in this study, with 73.3% of the patients feeling no discomfort at all (a composite score of 0 for pain, heat and coldness) and 21.5% reporting very mild discomfort (a composite score of 1--3 out of a possible total of 30). This result is consistent with the findings of many previous studies.^[@b6],[@b9]^

The major strength of this study is that a large number of patients undergoing routine imaging examinations were included in various types of examinations across a large number of centres. This minimizes bias caused by single-centre and/or single-indication effects, and thus increases applicability of the study results to daily clinical practice. As a PMS study, it was also performed strictly according to GCP/International Conference on Harmonisation standards protecting participants\' rights by obtaining informed consent either from patients directly or from their legal surrogates where the consent could not be obtained from the patient because of the use of sedative or anaesthetic drugs.

On the other hand, this study has some usual limitations inherent to the observational study, such as no randomization/blinding, no reference standard and no uniform standard to assess baseline risk factors and adverse events in the participating study centres.

In conclusion, iodixanol administration in 20 185 patients for various imaging examinations during routine clinical practice demonstrated a reassuring safety profile that is consistent with clinical trial data and previous clinical experience with ICM applications. The present study also confirmed that iodixanol is a well-tolerated contrast medium with an excellent comfort profile.
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